Geoffrey Shouse

Clinical trials

• Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

  Principal investigator · Not yet recruiting · Phase 2

  City of Hope Medical Center

  2026–2028
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  Principal investigator · Recruiting · Phase 2

  City of Hope Medical Center

  2026–2029
• Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  Principal investigator · Recruiting · Phase 1

  City of Hope Medical Center

  2025–2029
• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  Site PI · Recruiting · Phase 2

  Allogene Therapeutics

  2024–2032